CellaVision AB: Interim report January - September 2017

2017-10-25 - English

An in-between quarter though with stronger market presence as well as product sales approval in the USA

1 juli-30 september 2017   1 januari-30 september 2017
  • Net sales decreased by 10 % to SEK 61.3 million (68.3)
  • Organic growth was -11 % (-9).
  • Operating profit decreased by 47.3 % to SEK 10.2 million (19.5).
  • The operating margin decreased to 16.7% (28.5).
  • Profit before tax decreased to SEK 9.9 million (19.8).
  • Earnings per share decreased to SEK 0.32 (0.64).
  • Cash flow decreased to SEK 5.6 million (7.4).
 
  • Net sales increased by 21.3 per cent to SEK 233.2 million (192.3). 
  • Organic growth was 19.5 % (6.1).
  • Operating profit increased by 31.8 % to SEK 69.2 million (52.5).
  • The operating margin increased to 29.7% (27.3).
  • Profit before tax decreased to SEK 68.6 million (55.0).
  • Earnings per share increased to SEK 2.2 (1.76).
  • Cash flow before dividend decreased to SEK 32.4 million (34.1).
 
    Significant events after the period close
   
  • CellaVision signed a distribution agreement with Boule Diagnostics
    prior to the launch in 2018 of product for small and medium-sized laboratories.

CEO's comments
After six quarters of good growth in the human healthcare segment CellaVision experienced negative sales growth in the third quarter of the year. CellaVision has an uneven order flow with variation between quarters. Accumulated growth for the first nine months was 21 percent and is in line with the previously communicated target of 15 percent annual growth over an economic cycle. Our assessment is that CellaVision's future development in the short and long term is unchanged positive.

For the quarter, sales decreased by ten percent to SEK 61.3 million (68.3) compared with the same period in the previous year, when sales growth was 50 percent in the human healthcare market. Exchange rate impact in the quarter was slightly positive; plus one percent. The operating profit was SEK 10.2 million (19.5), equivalent to an operating margin of 16.7 percent (28.5). The lower operating margin is mainly explained by a lower sales volume.

Market development
Sales in the Americas fell by about eleven percent compared with the same period in the previous year, which was a quarter that experienced growth of 30 percent in the human healthcare market. Apart from the strong comparative figures, the quarter's decrease is explained by some buildup of inventories in previous quarters by CellaVision's various distribution partners. However, the number of customer installations and CellaVision's end customer penetration continued to grow at a steady rate.

EMEA again reported a quarter with sound sales growth; about 23 percent. It is worth noting, however, that the comparative quarter in 2016 for EMEA was relatively weak.

Sales in APAC decreased by 28 percent in the third quarter of the year compared with the same period in the previous year. Despite the decrease compared with the corresponding quarter in 2016 the underlying trend is positive for the region as a whole. Sales in China continued to show strength, while other markets in the region saw a weaker quarter. 

Geographical expansion: United Kingdom / Ireland
CellaVision is continuing to establish local organizations for market support in priority markets and establishment of the organization in the United Kingdom/Ireland during the quarter was part of this. This establishment means that CellaVision now has 12 local organizations for market support that gives the company a presence in a total of 25 countries. Establishing local organizations for market support is a key strategy for securing sustainable growth globally and CellaVision is planning for further establishments during the year.

The veterinary market
CellaVision is continuing its long-term marketing activities in the veterinary market, and in the previous quarter, a distribution agreement was signed with Sysmex in the Americas.

Distribution expansion prepares launch of new technology platform
Progress on the new technology platform is going according to plan, with considerable investments in research and development. Apart from this, there are production preparations and marketing activities ahead of the launch that is planned for the second half of 2018 for the markets that do not require FDA or equivalent certification based on clinical validation.

In preparation for the coming launch of the new technology platform, with analyzers for small and mid-size labs in both the human healthcare and veterinary markets, CellaVision entered into a global distribution agreement with Boule Diagnostics. The company is active in the segment for small and mid-size labs and thus an important partner for ensuring future access to digital morphology for this type of lab. Discussions are in progress with more distribution partners in this segment.

FDA clearance of the CellaVision® Advanced RBC Application
During the quarter was the CellaVision® Advanced RBC Application, a software application that speeds up and simplifies morphological assessment of red blood cells, was cleared by the US regulatory authority, the FDA. This makes the product commercially available in the USA and globally, since the application has already been approved and launched in CellaVision's other markets.

Zlatko Rihter,
President and Chief Executive Officer

Key Ratios          
(MSEK) Jul-Sep 2017 Jul-Sep 2016 Jan-Sep 2017 Jan-Sep 2016 Jan-Dec 2016
Net sales 61.3 68.3 233.2 192.3 265.0
Gross profit 43.2 47.9 167.8 136.2 188.9
EBITDA 12.4 21.5 75.5 58.6 82.4
Operating profit 10.2 19.5 69.2 52.5 74.2
Operating margin, % 16.7 28.5 29.7 27.3 28.0
Profit/loss before tax 9.9 19.8 68.6 55.0 75.8
Cash flow for the period 5.6 7.4 -3.4 -1.6 25.8
Equity ratio, % 82.7 79.9 82.7 79.9 80.4

 

Questions concerning the interim report can be addressed to:
Zlatko Rihter, CEO, CellaVision AB, Tel: +46 (0) 733-62 11 06, E-mail: zlatko.rihter@cellavision.com
Magnus Blixt, CFO, CellaVision AB, Tel: +46 (0) 708-33 81 68, E-mail: magnus.blixt@cellavision.com

About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the mother company in Lund and by the market support organizations in the US, Canada, China, Japan, Dubai, Korea, Australia, France, Germany, Brazil and Great Britain. 
In 2016 sales were SEK 265 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Small Cap list. Read more at www.cellavision.com
 

PDF version: CellaVision AB Interim Report January -September 2017

Subscribe to updates

It's possible to subscribe to CellaVision's press releases, financial information by e-mail and SMS.

Click here to register


Information request

Are you looking for some particular information about our company or our business?

Click here to get in touch


Analyst

ABG Sundal Collier AB
Sten Gustafsson
+46 8 566 286 93

Pareto Securities AB
Christian Lee
+46 8 402 52 67

 

Access our Student Resources

To access this resource, please provide the following information about yourself.